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Although often overlooked, the primary goal for treating 
coronary artery disease is to decrease the risk of myocardial 
infarction (MI) and consequently reducing death, and the relief 
of anginal symptoms. While in the setting of acute coronary 
syndrome, the role of myocardial revascularization is well 
established, interventional procedures in patients with stable 
disease, especially percutaneous coronary intervention (PCI), 
remains controversial.
In this context, the recently published ORBITA trial[1] in The 
Lancet journal, has brought important responses to this debate, 
involving unconventional and disruptive concepts in the field 
as placebo and nocebo effects. As the first blinded randomized, 
placebo-controlled trial to test the efficacy of drug eluting stents 
versus optimized medical treatment (OMT), the study enrolled 
230 patients with stable angina and coronary artery stenosis ≥ 
70% to receive a sham versus current PCI. During 6 weeks after the 
false or true procedure, both groups underwent to OMT, and the 
endpoints of exercise time, peak O2 consumption and control of 
angina were compared. Coronary lesions had mean area stenosis 
of 84.4%, and fractional flow reserve of 0.69. No significant 
difference in the primary endpoint of exercise time increment 
between groups (PCI minus placebo 16.6 s, 95% CI  – 8.9 to 42 
–  P=0.2) was observed and also no deaths reported. Serious 
adverse events included four pressure-wire related complications 
in the placebo group, and five major bleeding events, including 
two in the PCI group and three in the placebo group. Contrary to 
the concepts derived from previous non-randomized studies, the 
authors concluded that in patients with medically treated angina 
and severe coronary stenosis, PCI did not increase exercise time 
by more than the effect of a placebo procedure. 
These apparently surprising results are supported by an 
impressive methodological rigor and careful conduction of 
the study. The measurement of the placebo effect, with the 
creation of the sham group, is an innovation, and the researchers 
were impeccable in controlling bias. Another impressive point 
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was the strict clinical control: for 6 weeks, patients could call a 
cardiologist 24 hour by 7 days a week, who would evaluate their 
medications and make sure they were understanding side effects. 
And medicines were adjusted a couple of times a week to get 
people maximally tolerated antianginal therapy.
As the key message, ORBITA delivered that the common 
clinical observation of symptomatic improvement from PCI 
might well contain a large placebo component. 
Previously to the ORBITA trial, the benefits of routine 
revascularization in stable ischemic heart disease have 
been questioned, in terms of death and MI rates, in several 
randomized studies: Medicine, Angioplasty or Surgery Study 
(MASS II), Clinical Outcomes Utilizing Revascularization and 
Aggressive Drug Evaluation (COURAGE), Bypass Angioplasty 
Revascularization Investigation 2 Diabetes (BARI 2D) and more 
recently, the ongoing International Study of Comparative 
Health Effectiveness with Medical and Invasive Approaches 
(ISCHEMIA) trial.
In the MASS II trial[2], 611 patients with proximal multivessel 
disease and documented ischemia were randomly assigned 
to coronary artery bypass grafting (CABG), PCI, or OMT. The 
10-year mortality rates in the 3 groups were 25.1%, 24.9%, and 
31.0%, respectively (P=0.09). The 10-year MI rates were 10.3%, 
13.3%, and 20.7%, respectively (P<0.01). Freedom from angina 
at 10 years was 64% with CABG, 59% with PCI, and 43% with 
OMT (P<0.001).
In the COURAGE trial[3], randomization of 2.287 patients to 
PCI plus OMT versus OMT alone did not reduce the long-term 
rate of death or MI. Nor, however, did PCI worsen prognosis, and 
crossover to PCI for progressive symptoms or acute coronary 
syndrome was required in 32% of OMT patients during a 
median 4.6-year follow-up. Moreover, patients randomized 
to PCI had less documented angina, were more likely to be 
angina-free (despite requiring fewer nitrates and calcium-
channel blockers), and had improved quality of life for up to 
3 years (8.35). The reduction in angina (assessed by the Seattle 
Angina Questionnaire) with PCI versus OMT was most evident 
only in those with the greatest level of baseline angina.
In the BARI 2D trial[4], 2.368 patients with type 2 diabetes 
(90% with stable ischemic heart disease) were randomized to 
prompt revascularization with intensive medical therapy (MT) or 
to intensive MT alone, with randomization stratified by intended 
PCI versus CABG. The 5-year rates of death (the primary endpoint) 
and major adverse cardiac events (MACE – death, MI, or stroke) 
were not significantly different with either strategy. However, 
patients in the CABG stratum had more advanced coronary 
artery disease (including more triple-vessel and proximal left 
anterior descending coronary artery disease) than those in 
the PCI stratum, and patients randomized to CABG versus 
intensive MT had lower 5-year rates of MACE (22.4% vs. 30.5%; 
P=0.01), driven by less MI (7.4% vs. 14.6%). In patients with less 
extensive coronary artery disease, there was no difference in 
MACE with PCI versus intensive MT. Compared with intensive 
MT, prompt revascularization resulted in significantly greater 
freedom from angina for up to 4 years. Most measures of quality 
of life through the 4-year follow-up were also improved with 
routine revascularization compared with intensive MT only, and 
revascularization was ultimately required in 42% of MT patients 
during follow-up.
Of note, bare-metal stents (BMS) were used in most 
PCI versus MT trials, including the MASS II, COURAGE, and 
BARI 2D studies. In fact, first-generation drug-eluting stents 
(DES) may reduce recurrent ischemia compared with BMS, 
resulting in fewer hospitalizations for repeat revascularization. 
However, data from meta-analysis have been controversial to 
demonstrate advantage of DES in reducing late mortality or 
MI rate, comparing to BMS. Kirtane et al.[5] evaluated the safety 
and efficacy of DES among “real-world” patients and those 
enrolled in pivotal randomized clinical trials (RCTs) and data 
from 9,470 patients in 22 RCTs and from 182.901 patients in 
34 observational studies were included. In RCTs, no significant 
differences were observed in the long-term rates of death or MI 
after DES or BMS use for either off-label or on-label indications. 
Only in real-world observational studies, with greater numbers 
of patients but the admitted potential for selection bias and 
residual confounding, DES was associated with reduction of MI 
and mortality, 
The specific evaluation of patients with stable coronary 
disease who underwent implantation of BMS or DES, even 
showed more intriguing results. In the Norwegian Coronary 
Stent Trial (NORSTENT) trial[6], 9.013 patients were randomised 
to receive the implantation of DES or BMS. In the group 
receiving DES, 96% of the patients received either everolimus 
or zotarolimus-eluting stents. The primary outcome was a 
composite of death from any cause and nonfatal spontaneous 
MI, after a median of 5 years of follow-up. Secondary outcomes 
included repeat revascularization, stent thrombosis, and quality 
of life. There were no significant differences in the components 
of the primary outcome, and quality-of-life measures did not 
differ significantly between the two groups. Only the rates of 
repeat revascularization were lower in the group receiving DES.
On the other hand, the value of the decision making 
between aggressive or conservative approach of stable 
coronary disease, made after invasive study of coronary 
anatomy, has been questioned. In the ongoing International 
Study of Comparative Health Effectiveness with Medical and 
Invasive Approaches (ISCHEMIA) trial[7] (NCT01471522), the 
main difference in study design is to randomize patients with 
stable coronary disease to invasive or conservative strategies, 
before catheterization. This is a multicenter randomized 
controlled trial with a target enrollment about 5.000 patients 
with at least moderate ischemia on stress imaging. The primary 
aim is to determine whether an initial invasive strategy of 
cardiac catheterization and optimal revascularization (with 
PCI or CABG, as determined by the local heart team) plus OMT 
will reduce the primary composite endpoint of cardiovascular 
death or nonfatal MI, in stable patients with moderate or severe 
ischemia and medically controllable or absent symptoms, 
comparing with an initial conservative strategy. Enrollment 
began in late 2012 and is projected to end in 2017. Average 
follow-up will be approximately 3 years. There are currently 
around 300 participating sites in more than 30 countries. The 
ISCHEMIA Trial thus aims to address limitations of previous 
strategy trials by: 1) enrolling patients before catheterization, 
so that anatomically high-risk patients are not excluded; 2) 
enrolling a higher-risk group with at least moderate ischemia; 
3) minimizing crossovers; 4) using contemporary DES and 
physiologically guided decision making (FFR) to achieve 
complete ischemic (rather than anatomic) revascularization; 
and 5) being adequately powered to demonstrate whether 
routine revascularization reduces cardiovascular death or 
nonfatal MI in patients with stable ischemic heart disease (SIHD) 
and at least moderate ischemia. The results of the ISCHEMIA trial 
will have important implications regarding global guidelines 
for performance and reimbursement of revascularization 
procedures in patients with stable coronary disease.
However, while we wait the results of ISCHEMIA trial and 
other ongoing studies, the ORBITA study is the best designed 
trial comparing conservative and interventional strategies in 
patients with stable angina. The rigor with which the trial was 
carried out and the conclusion that PCI has a powerful placebo 
effect, should have impact in forthcomings guidelines of stable 
coronary disease.
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